Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Decera Clinical Education Oncology Podcast

Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations

10 Jan 2022

Description

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include:Approved and emerging treatment options for FLT3-mutated AMLManagement of adverse events associated with FLT3 inhibitorsTherapies for IDH1- and IDH2-mutated AMLIdentifying and managing differentiation syndrome associated with IDH1/2 inhibitorsPresenters:Sarah M. Tinsley, PhD, APRN, AOCNNurse PractitionerCourtesy Assistant ProfessorDepartment of Malignant HematologyMoffitt Cancer CenterUniversity of South FloridaTampa, Florida 

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.